Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2000
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2000, for Repligen Corporation, a biotechnology company developing therapeutic products for pediatric diseases, organ transplantation, and immune system disorders. The company's primary product lines include recombinant Protein A for antibody purification and therapeutic candidates such as secretin for autism and CTLA4-Ig for transplant rejection and autoimmune diseases.
Key Financial Metrics
| Metric | Q2 2000 | Q2 1999 |
|---|---|---|
| Total Revenues | $1,173,399 | $688,168 |
| Product Revenues | $555,794 | $232,470 |
| Investment Income | $512,605 | $46,538 |
| Net Loss | $(970,943) | $(422,587) |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.02) |
| Cash and Cash Equivalents | $26,014,851 | $11,817,472 |
| Marketable Securities | $7,821,730 | N/A |
| Total Current Assets | $35,028,744 | N/A |
| Total Current Liabilities | $785,968 | N/A |
| Working Capital | $34,242,776 | N/A |
Liquidity: The company reported total cash, cash equivalents, and marketable securities of approximately $33.8 million as of June 30, 2000. Management believes this is sufficient to meet working capital and capital expenditure requirements for the next 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 71% to $1.17 million, driven by a 139% increase in product sales (primarily recombinant Protein A) and a 991% surge in investment income due to higher cash balances from a March 2000 private placement.
- Expense Increases: Total expenses rose 93% to $2.14 million. Research and development (R&D) expenses increased 122% to $1.08 million, largely due to the acquisition of a patent application from Tolerance Therapeutics LLC and increased drug development costs. Selling, general, and administrative (SG&A) expenses increased 72% to $731,000 due to shareholder services and legal costs.
- Net Loss Expansion: The net loss widened to $971,000 from $423,000 in the prior year, reflecting the significant increase in operating expenses outpacing revenue growth.
- Customer Concentration: Two customers accounted for approximately 14% and 20% of revenues in Q2 2000, compared to 25% and 14% in Q2 1999.
Outlook, Risks, and Unusual Items
- Patent Acquisition: In May 2000, the company purchased rights to a U.S. patent application for CTLA4-Ig from Tolerance Therapeutics LLC, paying cash and issuing 30,000 shares of common stock. Additional cash payments may be required if certain conditions are met.
- Legal Proceedings: Repligen is pursuing a correction of inventorship regarding certain patents held by Bristol-Myers Squibb (BMS) related to CTLA4. A previous complaint was dismissed for lack of standing, but Repligen intends to continue pursuing the claim. Failure to obtain shared ownership could restrict commercialization of CTLA4-Ig.
- Regulatory Status: A New Drug Application for Secretin-Repligen-TM has been reviewed by the FDA, with approval pending administrative review. The product has orphan drug status. Approval is not guaranteed.
- Accounting Changes: The company is evaluating the impact of SAB No. 101 on revenue recognition for upfront fees and milestone payments but does not currently expect a significant impact.
Investor Verification Checklist
- Verify the status of the FDA review for Secretin-Repligen-TM and the likelihood of approval.
- Confirm the terms and potential future cash obligations associated with the Tolerance Therapeutics LLC patent purchase.
- Monitor the progress of the legal dispute with Bristol-Myers Squibb regarding CTLA4 patent inventorship.
- Assess the sustainability of investment income, which currently represents a significant portion of total revenue.
- Review the timeline and budget for clinical trials of secretin and CTLA4-Ig to ensure adequate funding remains available.